menu toggle

5 Years of Biosimilars in the US: What Have We Learned?

PharmaPhorum, Sean McGowan

Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients worldwide. In some cases, a painless injection is all that is now needed to mitigate and manage various cancers, rheumatoid arthritis, Crohn’s Disease, and other life-altering illnesses.

With patents on originator biologic medicines beginning to expire in the United States, there’s a growing opportunity for biosimilars to enter the market as alternative therapeutic options at lower prices. In fact, the success of biosimilars in Europe has given the United States a glimpse into how these therapies can increase patient access to the benefits of the most innovative therapies.

For the full article, check out PharmaPhorum